The role of epigenetics in hypertension of children and adolescents: a systematic review.

Blood PressDec 27, 2025 (epub)
Clinical ResearchPediatricsCardiology

Lilik Sukesi, Yunia Sribudiani, Steven Yulius Usman et al.

✦ AI-curated · Sources linked

In 30 seconds

This PRISMA 2020 systematic review qualitatively assessed 14 published studies on epigenetics and blood pressure in children and adolescents. Eleven studies (78.5%) reported a correlation between epigenetic factors and blood pressure, although the genes or loci examined differed across studies. Overall, the review found that epigenetic modifications involving various single nucleotide polymorphisms and other genes were associated with higher systolic and diastolic blood pressure. The findings indicate a possible relationship in young people, but the varied targets and qualitative synthesis do not establish a single mechanism or causal effect.

Key findings

  • Eleven of 14 included studies (78.5%) reported a correlation between epigenetic factors and blood pressure.
  • Across studies, epigenetic modifications involving various SNPs and other genes were associated with higher systolic and diastolic blood pressure.
  • The studies examined different genes or loci, limiting consistency in the specific epigenetic factors identified.

Why it matters

The review brings together evidence that epigenetic factors may be associated with blood pressure in childhood and adolescence, a period relevant to later cardiovascular health. The findings support continued investigation of how genetic and environmental influences relate to blood pressure, while the variation in genes and loci studied means the evidence does not yet point to a consistent clinical marker.

What to keep in mind

The review included 14 studies, assessed qualitatively, and the studies examined different genes or loci; the abstract does not report a pooled effect estimate.

Source

Published in Blood Press. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.